LY2090314 是GSK-3抑制剂，抑制 GSK-3α (IC50:1.5 nM) 和 GSK-3β (IC50:0.9 nM)。

LY2090314, an effective GSK-3α/β inhibitor (IC50: 1.5 nM/0.9 nM), may improve the efficacy of platinum-based chemotherapy regimens. LY2090314 has been used in trials studying the treatment of Leukemia, Advanced Cancer, and Pancreatic Cancer.

LY2090314 enhances the efficacy of cisplatin and carboplatin in solid tumor cancer xenografts. [1]

603288-22-8

C28H25FN6O3

512.53

DMSO:93 mg/mL (181.5 mM)
Ethanol:2 mg/mL (3.9 mM),warmed
Powder: -20°C for 3 years
In solvent: -80°C for 2 years